Literature DB >> 17187190

Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.

Takuya Sato1, Ken Watanabe, Masaaki Masuhara, Naoto Hada, Yoshiyuki Hakeda.   

Abstract

Osteoclastogenic cytokines produced by T and B lineage cells and interleukin (IL)-7-induced expansion of the pool size of osteoclast precursors have been suggested to play an important role in acceleration of osteoclastogenesis induced by estrogen deficiency. However, the contribution of increased RANKL produced by osteoblasts/stromal cells to increase osteoclastogenesis in a mouse model of estrogen-deficient osteoporosis and in vitro effects of IL-7 on osteoclast precursor generation remain controversial. Thus, we investigated the effect of ovariectomy (OVX) of mice on production of RANKL, osteoprotegerin (OPG), and IL-7 in bone and the effect of IL-7 on osteoclast precursor generation in vitro. OVX did not significantly stimulate mRNA expressions of RANKL and OPG in whole femurs. Because the epiphysis, but not the femoral shaft (diaphysis) or bone marrow, is the main site of osteoclastogenesis, it is important to specifically analyze mRNA expression by osteoblasts/stromal cells at these parts of the femur. Therefore, we isolated RNA from bone marrow cell-free epiphysis, diaphysis, and flushed-out bone marrow and examined mRNA expression. The results showed no significant changes of RANKL and OPG mRNA expression in any part of the femur. In addition, OVX did not significantly affect RANKL and OPG mRNA expression by the adherent stromal cells isolated from flushed-out bone marrow cells but did stimulate RANKL mRNA expression by B220(+) cells in the nonadherent cell fraction. On the other hand, OVX increased IL-7 mRNA expression in the femur as well as IL-7 concentrations in bone fluid. In cultures of unfractionated bone cells isolated by vigorous agitation of minced whole long bones to release the cells tightly attached to the bone surfaces, but not in cocultures of clonal osteoblasts/stromal cells and flushed-out bone marrow cells, IL-7 stimulated generations of osteoclasts as well as osteoclast precursors. These data suggest that increased RANKL production by osteoblasts/stromal cells is unlikely to play a central role in acceleration of osteoclastogenesis in estrogen deficiency of mice and that IL-7 stimulates osteoclast precursor generation, presumably through an action of IL-7 on the cells attached to bone rather than on cells contained in the bone marrow cell population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187190     DOI: 10.1007/s00774-006-0723-y

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  42 in total

1.  Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches.

Authors:  S K Nilsson; H M Johnston; J A Coverdale
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

2.  Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency.

Authors:  M Neale Weitzmann; Cristiana Roggia; Gianluca Toraldo; Louise Weitzmann; Roberto Pacifici
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

Authors:  L C Hofbauer; S Khosla; C R Dunstan; D L Lacey; W J Boyle; B L Riggs
Journal:  J Bone Miner Res       Date:  2000-01       Impact factor: 6.741

4.  Connection between B lymphocyte and osteoclast differentiation pathways.

Authors:  N Manabe; H Kawaguchi; H Chikuda; C Miyaura; M Inada; R Nagai; Y Nabeshima ; K Nakamura; A M Sinclair; R H Scheuermann; M Kuro-o
Journal:  J Immunol       Date:  2001-09-01       Impact factor: 5.422

5.  Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines.

Authors:  M N Weitzmann; S Cenci; L Rifas; C Brown; R Pacifici
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

6.  Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental organization and osteolysis.

Authors:  H O Valenzona; R Pointer; R Ceredig; D G Osmond
Journal:  Exp Hematol       Date:  1996-11       Impact factor: 3.084

7.  Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche.

Authors:  Fumio Arai; Atsushi Hirao; Masako Ohmura; Hidetaka Sato; Sahoko Matsuoka; Keiyo Takubo; Keisuke Ito; Gou Young Koh; Toshio Suda
Journal:  Cell       Date:  2004-07-23       Impact factor: 41.582

8.  Dynamics and localization of early B-lymphocyte precursor cells (pro-B cells) in the bone marrow of scid mice.

Authors:  D G Osmond; N Kim; R Manoukian; R A Phillips; S A Rico-Vargas; K Jacobsen
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

9.  Characterization of a novel bipotent hematopoietic progenitor population in normal and osteopetrotic mice.

Authors:  Claudine Blin-Wakkach; Abdelilah Wakkach; Nathalie Rochet; Georges F Carle
Journal:  J Bone Miner Res       Date:  2004-03-22       Impact factor: 6.741

10.  TRANCE together with IL-7 induces pre-B cells to proliferate.

Authors:  Ibuki Kato; Hiromu Sato; Akira Kudo
Journal:  Eur J Immunol       Date:  2003-02       Impact factor: 5.532

View more
  14 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice.

Authors:  Yuko Fujiwara; Marilina Piemontese; Yu Liu; Jeff D Thostenson; Jinhu Xiong; Charles A O'Brien
Journal:  J Biol Chem       Date:  2016-10-12       Impact factor: 5.157

3.  Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis.

Authors:  Chiyomi Hayashida; Junta Ito; Mai Nakayachi; Mari Okayasu; Yoko Ohyama; Yoshiyuki Hakeda; Takuya Sato
Journal:  J Biol Chem       Date:  2014-03-07       Impact factor: 5.157

4.  Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.

Authors:  Binhong Wen; Lu Zhao; Hongmei Zhao; Xiaochen Wang
Journal:  Exp Ther Med       Date:  2018-04-10       Impact factor: 2.447

Review 5.  How B cells influence bone biology in health and disease.

Authors:  Mark C Horowitz; Jackie A Fretz; Joseph A Lorenzo
Journal:  Bone       Date:  2010-06-18       Impact factor: 4.398

6.  The antidepressant bupropion exerts alleviating properties in an ovariectomized osteoporotic rat model.

Authors:  Hatem M Abuohashish; Mohammed M Ahmed; Salim S Al-Rejaie; Kamal E H Eltahir
Journal:  Acta Pharmacol Sin       Date:  2014-12-29       Impact factor: 6.150

Review 7.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

Review 8.  Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures.

Authors:  L M McNamara
Journal:  J R Soc Interface       Date:  2009-10-21       Impact factor: 4.118

9.  Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-kappaB p50/p65.

Authors:  Masaaki Masuhara; Takuya Sato; Naoto Hada; Yoshiyuki Hakeda
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

10.  A Special Ingredient (VtR) Containing Oligostilbenes Isolated from Vitis thunbergii Prevents Bone Loss in Ovariectomized Mice: In Vitro and In Vivo Study.

Authors:  Yu-Ling Huang; Yen-Wenn Liu; Yu-Jou Huang; Wen-Fei Chiou
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-11       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.